RT Journal
A1 McDiarmid TD, Hensel WA
T1 Coronary events with lipid-lowering therapy: The afcaps/texcaps trial
JF JAMA
JO JAMA
YR 1999
FD February 3
VO 281
IS 5
SP 414
OP 419
DO 10-1001/pubs.JAMA-ISSN-0098-7484-281-5-jbk0203
UL http://dx.doi.org/10-1001/pubs.JAMA-ISSN-0098-7484-281-5-jbk0203
AB 
It is unfortunate that other proven, less expensive forms of
primary prevention were not common in either the control or treatment
groups. For example, low-dose aspirin has been associated with a 33%
to 44% risk reduction for MI3- 4 but was part of the
treatment regimen in only 17% of the study patients. Similarly,
postmenopausal hormone replacement therapy has been associated with a
40% to 50% risk reduction4- 5 but was used by only about
30% of women in AFCAPS/TexCAPS. These therapies, if more prevalent in
the study population, would have decreased the number of coronary
events. Even if this factor did not decrease the power or significance
of the findings, it certainly would have increased the cost per acute
coronary event prevented.